Topics:
Gastrointestinal Cancers • Medical Oncology
What is the role of EGFR inhibitors in patients with metastatic transverse colon cancer?
Would you offer them as second line?
Answer from: Medical Oncologist at Academic Institution
The algorithm for use of EGFR antibodies in mCRC patients entails looking at the currently validated molecular markers (extended RAS, BRAF, and potentially HER2) and if the molecular markers are permissive, then consider sidedness.
Anatomically, transverse colon cancer is part of the right si...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
This is a very tricky question since all the studies including meta-analysis have not clearly addressed this question. If we believe the overall survival difference we observed is truly due to the primary tumor location (sidedness) that is possibly due to the right sided colon being from the midgut ...